Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects

Gastroenterology

Volumn 133, Issue 2, 2007, Pages 496-506

  Gastaldelli, Amalia ^a,b   Cusi, Kenneth ^a,b   Pettiti, Maura ^b   Hardies, Jean ^a   Miyazaki, Yoshinori ^a   Berria, Rachele ^a,c   Buzzigoli, Emma ^b   Sironi, Anna Maria ^b   Cersosimo, Eugenio ^a   Ferrannini, Ele ^a,d   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ADULT; AGE DISTRIBUTION; ANTHROPOMETRY; ARTICLE; BODY MASS; CLAMP; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LABORATORY TEST; LEAN BODY WEIGHT; LIVER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PRIORITY JOURNAL; SEX DIFFERENCE; SUBCUTANEOUS FAT;

EID: 34547514221     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.04.068     Document Type: Article

References (40)

1. Gastaldelli A., Miyazaki Y., Pettiti M., Buzzigoli E., Mahankali S., Ferrannini E., et al. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab 89 (2004) 3914-3921
2. Jeng C., Sheu W., Fuh M., Chen Y., and Reaven G. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 43 (1994) 1440-1444
3. Groop L.C., Bonadonna R.C., DelPrato S., Ratheiser K., Zyck K., Ferrannini E., et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84 (1989) 205-213
4. Bugianesi E., McCullough A.J., and Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005) 987-1000
5. Barzilai N., She L., Liu B.Q., Vuguin P., Cohen P., Wang J., et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 48 (1999) 94-98
6. Bajaj M., Suraamornkul S., Hardies L.J., Pratipanawatr T., and DeFronzo R.A. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord 28 (2004) 783-789
7. Bjorntorp P. Metabolic abnormalities in visceral obesity. Ann Med 24 (1992) 3-5
8. Wyatt S.B., Winters K.P., and Dubbert P.M. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 331 (2006) 166-174
9. Marceau P., Biron S., Hould F.S., Marceau S., Simard S., Thung S.N., et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84 (1999) 1513-1517
10. Knobler H., Schattner A., Zhornicki T., Malnick S.D., Keter D., Sokolovskaya N., et al. Fatty liver-an additional and treatable feature of the insulin resistance syndrome. QJM 92 (1999) 73-79
11. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., Goto T., Westerbacka J., Sovijarvi A., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87 (2002) 3023-3028
12. Bugianesi E., Gastaldelli A., Vanni E., Gambino R., Cassader M., Baldi S., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48 (2005) 634-642
13. Ryysy L., Hakkinen A.M., Goto T., Vehkavaara S., Westerbacka J., Halavaara J., et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49 (2000) 749-758
14. Kelley D.E., McKolanis T.M., Hegazi R.A., Kuller L.H., and Kalhan S.C. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol 285 (2003) E906-E916
15. Garg A., and Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 87 (2002) 3019-3022
16. Cree M.G., Newcomer B.R., Katsanos C.S., Sheffield-Moore M., Chinkes D., Aarsland A., et al. Intramuscular and liver triglycerides are increased in the elderly. J Clin Endocrinol Metab 89 (2004) 3864-3871
17. DeFronzo R., Tobin D., and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237 (1979) E214-E223
18. Bonora E., Del Prato S., Bonadonna R., Gulli G., Solini A., Shank M., et al. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes 41 (1992) 1151-1159
19. Lancaster J., Ghiatas A., Alyassin A., Kilcoyne R., Bonora E., and DeFronzo R. Measurement of abdominal fat with T1-weighted MR images. J Magn Reson Imaging 1 (1991) 363-369
20. Schumann W.C., Gastaldelli A., Chandramouli V., Previs S.F., Pettiti M., Ferrannini E., et al. Determination of the enrichment of the hydrogen bound to carbon 5 of glucose on 2H2O administration. Anal Biochem 297 (2001) 195-197
21. Landau B.R., Wahren J., Chandramouli V., Schumann W.C., Ekberg K., and Kalhan S.C. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 98 (1996) 378-385
22. Gastaldelli A., Baldi S., Pettiti M., Toschi E., Camastra S., Natali A., et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49 (2000) 1367-1373
23. Previs S., Hazey J., Diraison F., Beylot M., David F., and Brunengraber H. Assay of the deuterium enrichment of water via acetylene. J Mass Spectr 31 (1996) 389-391
24. Natali A., Toschi E., Camastra S., Gastaldelli A., Groop L., and Ferrannini E. Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. European Group for the Study of Insulin Resistance (EGIR). Diabetologia 43 (2000) 1266-1272
25. Altszuler N., De Bodo R.C., Steele R., and Wall J.S. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187 (1956) 15-24
26. Sindelar D.K., Chu C.A., Venson P., Donahue E.P., Neal D.W., and Cherrington A.D. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 47 (1998) 523-529
27. DeFronzo R.A., Ferrannini E., and Simonson D.C. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38 (1989) 387-395
28. Gastaldelli A., Miyazaki Y., Pettiti M., Matsuda M., Mahankali S., Santini E., et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 87 (2002) 5098-5103
29. Miyazaki Y., Glass L., Triplitt C., Wajcberg E., Mandarino L.J., and DeFronzo R.A. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol 283 (2002) E1135-E1143
30. Eguchi Y., Eguchi T., Mizuta T., Ide Y., Yasutake T., Iwakiri R., et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol 41 (2006) 462-469
31. Marchesini G., Brizi M., Morselli-Labate A.M., Bianchi G., Bugianesi E., McCullough A.J., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 (1999) 450-455
32. Haque M., and Sanyal A.J. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 16 (2002) 709-731
33. Sanyal A., Campbell-Sargent C., Mirshahi F., Rizzo W., Contos M., Sterling R., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
34. Kabir M., Catalano K.J., Ananthnarayan S., Kim S.P., Van Citters G.W., Dea M.K., et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol 288 (2005) E454-E461
35. Bajaj M., Suraamornkul S., Pratipanawatr T., Hardies L.J., Pratipanawatr W., Glass L., et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52 (2003) 1364-1370
36. Gastaldelli A., Miyazaki Y., Pettiti M., Santini E., Ciociaro D., Defronzo R.A., et al. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J Clin Endocrinol Metab 91 (2006) 806-812
37. Samuel V.T., Liu Z.X., Qu X., Elder B.D., Bilz S., Befroy D., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279 (2004) 32345-32353
38. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
39. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
40. Matsuda M., and DeFronzo R.A. Relationship between insulin sensitivity in adipose tissue, liver, muscle and components of the insulin resistance syndrome. Diabetes 46 (1997) 68A